Cost of Illness Analysis of Pelvic Inflammatory Disease in Nigeria: a Developing Economy. Nigerian

No Thumbnail Available

Date

2022-04

Journal Title

Journal ISSN

Volume Title

Publisher

Nigerian Journal of Pharmaceutical and Biomedical Research

Abstract

Background: Pelvic inflammatory disease (PID) is a leading cause of infertility, ectopic pregnancies and psychological trauma, thus, representing a major public health concern and high economic burden for women in their reproductive ages. Objective: To conduct cost of illness analysis (COI) of PID in patients in University of Ilorin, Teaching Hospital, Ilorin, Kwara state, North- central Nigeria. Methods: A one year retrospective review of 2560 case notes of PID patients of which 396 were selected as the sample size from January 2021 to December 2021, in outpatient clinic of university of Ilorin teaching hospital. The selection of the 396 cases was done using systematic random sampling with sample interval of 5. Cost of Illness was determined by prevalence rate method, using direct costs only. Results: The annual cost of illness for the 396 PID patients on antibiotics was N4,418,16310,646 USD with drugs, diagnostic/monitoring tests, transportation, consultation fees and personnel cost components of 1,780 USD (16.73%), 4,161 USD (39.09%),666USD (6.26%),1778(16.70%), 2259 USD( 21.22%) respectively. The annual average national cost of illness of PID was N 11, 156.97 (26.86 USD) Conclusion: The annual average national cost of illness of PID represents 30.9 % of annual health expenditure per capita. This is not particularly high when compared with PID COI estimates achieved for some developed countries. The Annual National cost of illness for PID in Nigeria, a developing economymay beabout 69 million USD annually.

Description

Keywords

Analysis, Cost of Illness, Developing Economy, PID

Citation

Giwa H. B., Giwa A, Jamiu M.O.,Abolarin B.A., Saadu R.A (2022). Cost of Illness Analysis of Pelvic Inflammatory Disease in Nigeria: a Developing Economy. Nigerian Journal of Pharmaceutical and Biomedical Research, 6 (1): 123-131

Collections